An Overview of the Company

Meridian Lab is a biopharmaceutical specialty company focusing on the
discovery and development of cancer treatments through formulation
improvements.  The company owns patents on docetaxel and other  formulations
using the derivatives of beta-cyclodextrin.  Since 2006 the company has been
conducting research activities and in early 2010 the company was
incorporated as a Delaware C Corp.

The company¹s lead product, ML061, is an IP protected reformulation of
Taxotere in Captisol that eliminates Polysorbate 80 and its associated
"Black Box" side effects.

Our technology has wide therapeutic applications.  We are actively expanding
our portfolio.